Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure

Bibliographic Details
Main Authors:	Frederik H. Verbrugge, Barry A. Borlaug
Format:	Article
Language:	English
Published:	Wiley 2020-07-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	Editorials angiotensin receptor–neprilysin inhibitor right ventricle–pulmonary arterial coupling
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.120.017292

Similar Items

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
by: Tomoko Kato, et al.
Published: (2023-09-01)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
by: Toshio Nishikimi, et al.
Published: (2022-07-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
by: Yusuke Kashiwagi, et al.
Published: (2023-06-01)

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
by: Donna S.‐H. Lin, et al.
Published: (2021-03-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
by: A.S. Ryazanov, et al.
Published: (2023-04-01)

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime
by: Alessandra Arcudi, et al.
Published: (2022-10-01)

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
by: Teng Y, et al.
Published: (2023-08-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
by: A. S. Ryazanov, et al.
Published: (2023-01-01)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
by: Brittany Chapman, et al.
Published: (2022-06-01)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
by: Su Yeong Park, et al.
Published: (2023-09-01)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
by: Amrita Mukhopadhyay, et al.
Published: (2022-12-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury
by: Sahmin Lee, et al.
Published: (2021-08-01)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
by: Kangbo Li, et al.
Published: (2023-02-01)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)

Anti-hypertensive effect of a novel angiotensin II receptor neprilysin inhibitor (ARNi) -S086 in DSS rat model
by: Jingchao Sun, et al.
Published: (2024-02-01)

Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
by: Julie Hempel Larsen, et al.
Published: (2023-02-01)

Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data
by: Alvaro Alonso, et al.
Published: (2024-03-01)

Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary
by: Masafumi Sato, et al.
Published: (2021-03-01)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
by: Wanjing Li, et al.
Published: (2022-04-01)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
by: Hyuk Kyoon Park, et al.
Published: (2023-12-01)

Protective effect of novel angiotensin receptor neprilysin inhibitor S086 on target organ injury in spontaneously hypertensive rats
by: Ying Xiao, et al.
Published: (2024-01-01)

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection
by: Shunichiro Tsukamoto, et al.
Published: (2023-04-01)

Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
by: Xiaobo Wang, et al.
Published: (2023-07-01)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
by: Alessandro Bellis, et al.
Published: (2020-11-01)

Angiotensin receptor neprilysin inhibitor in heart failure with reduced ejection fraction: Real-world experience from a safety perspective
by: Manas Layek, et al.
Published: (2020-01-01)

Blockade of the Neprilysin and Angiotensin Ameliorates Oxidative Stress in the Cardiovascular Target Tissues of Dexamethasone-induced Hypertensive Rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-01-01)

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
by: Jamshed Dalal, et al.
Published: (2023-06-01)

Relevance of Neutrophil Neprilysin in Heart Failure
by: Suriya Prausmüller, et al.
Published: (2021-10-01)

It's All About That Right Ventricle
by: Ambreen F. Ali, et al.
Published: (2024-04-01)

Angiotensin Receptor–Neprilysin Inhibition (Sacubitril/Valsartan) Reduces Structural Arterial Stiffness in Middle‐Aged Mice
by: Isabel N. Schellinger, et al.
Published: (2024-02-01)

The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis
by: Yanxia Lin, et al.
Published: (2022-05-01)

Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy
by: Wei-Chieh Lee, et al.
Published: (2023-04-01)

Neurohumoral Activation in Heart Failure
by: Antonis A. Manolis, et al.
Published: (2023-10-01)

Echocardiographic Assessment of Right Ventricular–Arterial Coupling in Predicting Prognosis of Pulmonary Arterial Hypertension Patients
by: Remigiusz Kazimierczyk, et al.
Published: (2021-07-01)

Pulmonary hypertension and heart failure: alternative indexes of right ventricular-pulmonary artery coupling
by: V. A. Mareyeva, et al.
Published: (2023-10-01)